Cargando…
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Padron et al.(1) studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589119/ https://www.ncbi.nlm.nih.gov/pubmed/36260984 http://dx.doi.org/10.1016/j.xcrm.2022.100788 |
| _version_ | 1784814230197764096 |
|---|---|
| author | Melief, Cornelis J.M. |
| author_facet | Melief, Cornelis J.M. |
| author_sort | Melief, Cornelis J.M. |
| collection | PubMed |
| description | Padron et al.(1) studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination |
| format | Online Article Text |
| id | pubmed-9589119 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95891192022-10-25 Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? Melief, Cornelis J.M. Cell Rep Med Spotlight Padron et al.(1) studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination Elsevier 2022-10-18 /pmc/articles/PMC9589119/ /pubmed/36260984 http://dx.doi.org/10.1016/j.xcrm.2022.100788 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Spotlight Melief, Cornelis J.M. Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title | Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title_full | Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title_fullStr | Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title_full_unstemmed | Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title_short | Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| title_sort | two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? |
| topic | Spotlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589119/ https://www.ncbi.nlm.nih.gov/pubmed/36260984 http://dx.doi.org/10.1016/j.xcrm.2022.100788 |
| work_keys_str_mv | AT meliefcornelisjm twotypesofbiomarkerdependentchemoimmunotherapyforpancreaticcancer |